This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

The COVID-19 studies on our website have moved.

Please visit the list of nationally prioritised studies.